Evidence map›Paper›PMID 40666845›Full record

ArticlebioRxiv : the preprint server for biology2025

Genetically-programmed Hypervesiculation of

Nicholas H Pirolli, Daniel Levy, Alyssa Schledwitz, Natalia Sampaio Moura, Talia J Solomon, Emily H Powsner, Raith Nowak, Zuzanna Mamczarz, Christopher J Bridgeman, Sulayman Khan and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Nicholas H PirolliFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Daniel LevyFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Alyssa SchledwitzDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, United States.
Natalia Sampaio MouraDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, United States.
Talia J SolomonFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Emily H PowsnerFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Raith NowakFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Zuzanna MamczarzFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Christopher J BridgemanFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Sulayman KhanFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Laura ReusFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Nidhi AnneFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
William E BentleyFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Jean-Pierre RaufmanDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, United States.
Steven M JayFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.ORCID 0000-0002-3827-5988

Funding

Research Training in Gastroenterology and HepatologyT32DK067872 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI RAUFMAN, JEAN-PIERRE · 2005 to 2024
$7.2M
Controlling Exosome Noncoding RNA Cargo for Enhanced Wound HealingR01HL141611 · NHLBI · UNIV OF MARYLAND, COLLEGE PARK · PI JAY, STEVEN MICHAEL · 2018 to 2022
$1.9M
BLRD VA I01 BX004890FDA HHS U01 FD005946NHLBI NIH HHS R01 HL141611NIDDK NIH HHS T32 DK067872
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD) affect over 6 million people globally and current treatments achieve only 10-20% rates of durable disease remission. Bacterial extracellular vesicles (BEVs) from probiotic lactic acid bacteria (LAB) are a promising novel therapeutic with mechanisms holding potential to drive increased rates of durable disease remission, including immunomodulation and intestinal epithelial tissue repair. However, translation of these cell-secreted nanovesicles is limited by long standing biomanufacturing hurdles, especially low production yields due to low biogenesis rates from cells. Here, our goal was to identify a candidate probiotic LAB that produces BEVs effective in a preclinical mouse model of IBD, and then genetically engineer the LAB for at least 10-fold increased production yields of BEVs, thereby passing a critical production threshold. We identified

Indexed as

bacterial membrane vesiclescolitisextracellular vesiclesIBDlactic acid bacteria

Identifiers

PMID40666845
PMCPMC12262237

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.